Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-2: Tabalumab in Systemic Lupus Erythematosus
NCT01205438Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Primary completion
- Aug 2014
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of tabalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Systemic Lupus Erythematosus Responder Index Response at 52 weeks. Started Jan 2011; status: completed.
02
Drugs
tabalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01205438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205438.